Sunday, June 21, 2015 8:53:06 AM
Brean Capital analyst Difei Yang reiterated a Buy rating and boosted its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $31.00 (from $25.00) on high likilihood of Glatopa being the only generic Copaxone on market for extended period of time.
"Due to an earlier-than-expected launch (June vs. our estimation of September, 2015) coupled with the expected favorable competitive market condition, i.e., less price discount, more market share, we are significantly revising our EPS estimates up," Yang commented. "As a result, our price target increases from $25 to $31."
http://www.streetinsider.com/Analyst+Comments/Momenta+Pharmaceuticals+(MNTA)+PT+Raised+to+$31+at+Brean+Capital/10665045.html
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM